Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 1.03% 49.00 48.00 50.00 49.00 48.50 48.50 44,036 15:33:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.7 -3.6 -5.7 - 7

Netscientific Share Discussion Threads

Showing 2651 to 2674 of 2675 messages
Chat Pages: 107  106  105  104  103  102  101  100  99  98  97  96  Older
DateSubjectAuthorDiscuss
14/1/2021
14:05
Yep but need to see decent rise and stable increase. Been in this range way to long....
samsung2020
14/1/2021
14:03
PDS Biotech Releases White Paper Detailing the Potential of the Versamune(R) Platform in Overcoming a Major Limitation of Immuno-Oncology Good news at last
jerseysteve
06/1/2021
10:05
Needs news mate, hopefully the stuff Brazil gets moving soon and this has a decent impact on NSCI. It's been super quiet on this stock since July so surely something soon - I hope :)
samsung2020
06/1/2021
09:55
Talk about the quiet place!
loafofbread
24/12/2020
10:34
Hope so mate. Have a nice Xmas.
samsung2020
24/12/2020
10:31
Just Proaxsis and PDSB cover our market cap imho, the rest is option money. Concert party at 42% and placing at 65p gives direction of travel. Expect some serious newsflow come the New Year.
loafofbread
22/12/2020
22:49
No doubt that is super cheap and when it does rise,multibag for sure at current rate. I've bought in a lot higher and would have liked it at least double of current price by now
samsung2020
22/12/2020
22:29
I'm more than happy to be able to buy a worthwhile position at this price. A bit like an investment trust, but 100%+ below NAV!
loafofbread
22/12/2020
22:20
Evening gents. Must confess, slightly disappointed we haven't seen a decent spike here in quite some time. Lots of time it's got going but not really materialised. Was hoping for close to 90p on Xmas day, don't see it now.... Interested in views..
samsung2020
16/12/2020
10:37
How, it would be 4.5p! It was a 10:1
charlie88888
16/12/2020
09:04
Now 2.3p old money - I think - e&oe - Confirmation please?
pugugly
10/12/2020
07:25
Great news Hopefully we see solid blue movement here today.
samsung2020
10/12/2020
07:17
ProAxsis awarded Innovate UK grant. Great news
jerseysteve
06/12/2020
21:03
Some chap on Twitter wrote this....#NSCI due a rise with $PDSB up 27% on Friday following a new broker target of $7:00. Recent placing in NSCI was 65p with multiple investments the cash and value of PDSB means no value attributed to any of there other companies.
samsung2020
04/12/2020
22:12
PDSB lovely gap that needs closing between $3 and $4 I expect next major news challenge/take out $5 year high
the stigologist
04/12/2020
15:39
Will be over 60p xmas day
professor_az
04/12/2020
15:39
Finally a bit of blue
blakieboy7
04/12/2020
15:10
PDSB now 26% up, surely we will see movement here asap
samsung2020
04/12/2020
15:03
News from Brazil next week ?
nextlink
03/12/2020
13:45
ProAxsis Limited recognised as Gold Level Innovator by Innovate NI DECEMBER 2, 2020-POSTED BY DAVID RIBEIRO ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as a Gold Level Innovator in the Innovate NI Innovation Accreditation programme. The company has been recognised due to it continually demonstrating its ability to transform innovate ideas into commercially successful products. Speaking about the recognition, Dr David Ribeiro, CEO of ProAxsis, commented: “Recognition of this kind from Innovate NI is a great testament to both the cutting-edge research being conducted by the ProAxsis team of scientists at our purpose-built laboratory in Belfast, and our ability to transition these exciting concepts in to commercially viable assets. ProAxsis has conducted a number of R&D projects supported by Invest Northern Ireland, which have successfully led to the launch of highly novel protease biomarker assays, and we remain extremely grateful for their ongoing support in propelling the company towards being a globally-renowned protease diagnostics company.” Innovate NI is a Department for the Economy programme, helping local businesses innovate successfully. It is delivered by Invest Northern Ireland, local councils and further education colleges. Dr Vicky Kell, Invest NI’s Director of Innovation, Research & Development, added: “Over the last 5 years, we have worked in partnership with ProAxsis and our innovation support, including R&D, has helped it to develop and bring to market new diagnostic products which are now sold globally. As this company has proven, innovation is the key to business resilience and growth and being recognised as a Gold level innovator is testament to the success of its innovation journey so far. With this commitment to innovation, I am confident ProAxsis will continue to develop ground-breaking diagnostics, ultimately benefiting patients around the World.” Any enquiries concerning ProAxsis’ work on protease biomarkers can be directed to info@proaxsis.com. About ProAxsis ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. This technology has been translated into a point-of-care test (NEATstik┬«), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik┬« enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D projects for a variety of targets remain a key area of focus. Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
loafofbread
02/12/2020
19:01
Stuggy wat happen?this share is dead d0g
prof_pwhite
30/11/2020
15:49
What are u chatting about stiggybiggy
prof_pwhite
30/11/2020
14:54
There's a pulse News on PDSB and Glycotest please thanks
the stigologist
Chat Pages: 107  106  105  104  103  102  101  100  99  98  97  96  Older
ADVFN Advertorial
Your Recent History
LSE
NSCI
Netscienti..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210116 16:18:35